Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Company
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Number of employees : 20 people.
Sales per Business
20202021Delta
Biomarkers1.67100%2.08100% +24.3%
SEK in Million
Sales per region
2021
United States1.2560%
European Union excluding Sweden0.5325.6%
Sweden0.3014.4%
SEK in Million
Managers
Name Title Age Since
Anders Rylander Chief Executive Officer & Director 50 2011
Cecilia Driving CFO, Head-Human Resource, IR & EVP 49 2016
Mattias Bergqvist Director-Clinical Development 50 -
Otti Bengtsson Gref Director-Research & Development 52 2020
Adam Germunder Operations Director 36 -
Jarl Ulf Birger Jungnelius, Dr. Independent Director 69 2014
Maria Holmlund Independent Director 64 2016
Jesper Söderqvist, Dr. Independent Director 54 2013
Henrik Osvald Independent Director 61 2019
Robert Dann Senior Vice President-Marketing 58 2020
Members of the board
Name Title Age Since
Lars Erik Holmqvist Chairman 62 2019
Anders Rylander Chief Executive Officer & Director 50 2011
Jarl Ulf Birger Jungnelius, Dr. Independent Director 69 2014
Maria Holmlund Independent Director 64 2016
Jesper Söderqvist, Dr. Independent Director 54 2013
Henrik Osvald Independent Director 61 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,875,512 11,915,580 54.5% 0 0.0% 41.9%
Stock B 0 6,542,860 0 0.0% 0 0.0%
Shareholders
NameEquities%
Coeli Asset Management AB 1,494,424 6.83%
Northern Light Management AB 954,401 4.36%
Henrik Osvald 624,106 2.85%
Lancelot Asset Management AB 610,000 2.79%
Gunnar Rylander 565,494 2.59%
Lars Erik Holmqvist 534,536 2.44%
LYM Consulting AB 493,814 2.26%
Andra AP-fonden 474,391 2.17%
Anders Rylander 379,756 1.74%
East Capital Financial Services AB 132,750 0.61%
Company contact information
Biovica International AB
Dag Hammarskjölds väg 54B
Uppsala Science Park
Uppsala 752 37

Phone : +46.18.44.44.830
Fax : +46.18.57.24.28
Web : http://www.biovica.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Biovica International AB (publ)